Global Ventricular Assist Devices Market 2019 to 2025

Global Ventricular Assist Devices Market 2019–2025
This market research report includes a detailed segmentation of the global ventricular assist devices market – By Product (Left Ventricular Assist Devices [LVAD], Right Ventricular Assist Devices [RVAD], and Biventricular Assist Devices [BIVAD]), By Design (Transcutaneous Ventricular Assist Devices and Implantable Ventricular Assist Devices), By Application (Bridge-to-Transplant [BTT] Therapy, Destination Therapy, Bridge-to-Recovery [BTR] Therapy, and Bridge-to-Candidacy [BTC] Therapy), and By Region (North America, Europe, Asia Pacific and Rest of the World)

Overview of the Global Ventricular Assist Devices Market Research
Infoholic’s market research report predicts that the global ventricular assist devices market will grow at a CAGR of 13.8% during the forecast period. The market has witnessed steady growth in the past few years and development in technology with the introduction of innovative products have increased the acceptance of heart assist devices in the market. The market is fueled by increase in the incidence of heart failure, lack of heart donors for transplantation, and increasing elderly population.
 
 
The market continues to grow and is one of the most widely used devices for the functioning of heart in cardiac failure and weakened heart patients. The market is getting revolutionized with the advancement in technology. Vendors are focusing towards new product launches, product approvals, and targeting towards end-user’s perspective. The market generates the revenue from the key players operating in this field and some of vendors are Medtronic plc, Reliant Heart Inc., Abbott Laboratories, Berlin Heart GmbH, Jarvik Heart, Inc., and ABIOMED, Inc.
According to Infoholic Research analysis, North America accounted for the largest share of the global ventricular assist devices market in 2018 and will retain high position during the forecast period. According to American Heart Association, an estimated 92.1 million population in the US have at least one type of CVD and by 2030 it is projected that 43.9% of the US adult population to have some form of CVD. Favorable reimbursement policies, availability of advanced technologies, and growing cardiovascular diseases will increase the adoption and demand of the devices in this region. The Asia Pacific is expected to grow during the forecast period, owing to factors such as high prevalence of cardiovascular diseases, increasing healthcare expenditure, and presence of huge population base.
By Product:
• Left Ventricular Assist Devices (LVAD)
• Right Ventricular Assist Devices (RVAD)
• Biventricular Assist Devices (BIVAD)
In 2018, the left ventricular assist devices segment occupied the largest share and is expected to grow at high CAGR during the forecast period. Increasing number of patients suffering from last-stage heart failure, advancement in technology such as effectiveness, high survival rate, and decreased risk of the devices makes the segment the most common among other VAD devices.
By Design:
• Transcutaneous Ventricular Assist Devices
• Implantable Ventricular Assist Devices

In 2018, the implantable ventricular assist devices segment occupied the largest share and is expected to grow at high CAGR during the forecast period.
By Application:
• Bridge-to-Transplant (BTT) Therapy
• Destination Therapy
• Bridge-to-Recovery (BTR) Therapy
• Bridge-to-Candidacy (BTC) Therapy
By application, the bridge-to-recovery (BTR) therapy generated the maximum revenue, thus accounting for more than 35% of the global ventricular assist devices market in 2018 and the segment is expected to grow at high CAGR during the forecast period. The destination therapy segment is expected to be the second highest growing segment during the forecast period.

By Regions:
• North America
• Europe
• APAC
• ROW

The market is dominated by North America, followed by Europe and Asia Pacific. US occupied the major share of the North American market due to the increasing disease prevalence and availability of advanced technologies.
Ventricular Assist Devices Market Research Competitive Analysis – The global ventricular assist devices market has massive growth opportunities in both developed and developing regions. The advancement and upgradation of devices will increase the competition among vendors. Many vendors are focusing on product approvals and developing innovative products to strengthen their product portfolio that intensifies the market competition. In October 2018, FDA approved HeartMate 3 left ventricular assist device developed by Abbott, as a destination therapy for patients with advanced heart failure. The approval device supported by the Momentum 3 trial showed a survival rate of 82.8% at two years with rates of suspected pump thrombosis at only 1.1%. Health Canada issued a Class IV License with conditions to HeartMate 3 left ventricular assist system developed by Thoratec Corporation in 2018. In 2018, Calon Cardio-Technology has launched a clinical trial of the UK's first artificial heart pump. In addition, other leading players are focusing in huge investments on research and development activities to develop new products to attain maximum share in the market.

Key vendors:
• Medtronic plc
• Abbott Laboratories
• ReliantHeart Inc.
• Berlin Heart GmbH
• Jarvik Heart, Inc.
• ABIOMED, Inc.
• BiVACOR
• Calon Cardio-Technology Ltd.
• LivaNova PLC
• Evaheart Medical USA, Inc. (Asahi Kasei Corp.)
• Fresenius Medical Care AG & Co. KGaA (XENIOS AG)
• Maquet GmbH (Getinge AB)
Key competitive facts –
• The market is highly competitive with all the players competing to gain market shares. Intense competition, rapid advancements in technology, frequent changes in government policies, and the prices are key factors that confront the market.
• The requirement of high initial investment, implementation, and maintenance cost in the market are also limiting the entry of new players.

Benefits – The report provides complete details about the usage and adoption rate of ventricular assist devices. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the medical devices segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.
Key Takeaways:
• Understanding the potential market opportunity with precise market size and forecast data
• Detailed market analysis focusing on the growth of ventricular assist devices industry
• Factors influencing the growth of ventricular assist devices market
• In-depth competitive analysis of dominant and pureplay vendors
• Prediction analysis of ventricular assist devices industry in both developed and developing regions
• Key insights related to major segments of the ventricular assist devices market
• Latest market trend analysis impacting the buying behavior of the consumers
 

Table of Contents

1 INDUSTRY OUTLOOK 8
1.1 Industry Overview 8
1.1.1 Geography 8
1.1.2 Medical Technologies 8
1.1.3 Industry Trends 10
1.2 Total Addressable Market 11
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 12
2.3 Research Methodology 13
2.4 Report Assumptions 14
3 Market Snapshot 15
3.1 Market Definition – Infoholic Research 15
3.2 Device Benefits 15
3.3 Segmented Addressable Market (SAM) 15
3.4 Trends in the Ventricular Assist Devices Market 16
3.5 Related Markets 17
3.5.1 Stents 17
3.5.2 Interventional Cardiology 17
3.5.3 Angioplasty 17
4 Market Outlook 18
4.1 Regulatory Status 18
4.2 Reimbursement 19
4.3 Market Segmentation 21
4.4 PEST Analysis 21
4.5 Porter 5(Five) Forces 23
5 Market Characteristics 24
5.1 DRO – Global Ventricular Assist Devices Market Dynamics 24
5.1.1 Drivers 25
5.1.1.1 Upsurge in the incidence of cardiovascular disease (CVD) 25
5.1.1.2 Growing geriatric population 25
5.1.1.3 Dearth of heart donors across the globe 26
5.1.2 Opportunities 26
5.1.2.1 Increased approvals, fun ding, and pipeline products 26
5.1.2.2 Upsurge in healthcare spending and demand for better treatment in emerging economies 27
5.1.3 Restraints 27
5.1.3.1 High cost of the devices 27
5.1.3.2 Strict regulatory policies 27
5.2 DRO – Impact Analysis 28
5.3 Key Stakeholders 29
6 Product: Market Size and Analysis 30
6.1 Overview 30
6.2 Left Ventricular Assist Devices 31
6.3 Right Ventricular Assist Devices 32
6.4 Biventricular Assist Devices 33
7 Design: Market Size and Analysis 35
7.1 Overview 35
7.2 Transcutaneous Ventricular Assist Devices 36
7.3 Implantable Ventricular Assist Devices 36
8 Applications: Market Size and Analysis 37
8.1 Overview 37
8.2 Bridge-to-Transplant (BTT) Therapy 38
8.3 Destination Therapy 39
8.4 Bridge-to-Recovery (BTR) Therapy 40
8.5 Bridge-to-Candidacy (BTC) Therapy 41
9 Regions: Market Size and Analysis 43
9.1 Overview 43
9.2 North America 44
9.3 Europe 46
9.4 Asia Pacific 47
9.5 Rest of the World 49
10 Competitive Landscape 51
10.1 Overview 51
11 Vendor Profiles 53
11.1 Medtronic plc 53
11.1.1 Overview 53
11.1.2 Business Units 58
11.1.3 Geographic Presence 59
11.1.4 Business Focus 59
11.1.5 SWOT Analysis 60
11.1.6 Business Strategies 60
11.2 Abbott Laboratories 61
11.2.1 Overview 61
11.2.2 Business Units 64
11.2.3 Geographic Presence 65
11.2.4 Business Focus 65
11.2.5 SWOT Analysis 66
11.2.6 Business Strategies 66
11.3 Reliant Heart Inc. 67
11.3.1 Overview 67
11.3.2 Business Focus 68
11.3.3 SWOT Analysis 68
11.3.4 Business Strategies 68
11.4 Jarvik Heart, Inc. 69
11.4.1 Overview 69
11.4.2 Business Focus 70
11.4.3 SWOT Analysis 70
11.4.4 Business Strategies 71
11.5 Berlin Heart GmbH 71
11.5.1 Overview 71
11.5.2 Business Focus 72
11.5.3 SWOT Analysis 72
11.5.4 Business Strategies 73
12 Companies to Watch For 74
12.1 BiVACOR 74
12.1.1 Overview 74
12.2 ABIOMED, Inc. 74
12.2.1 Overview 74
12.2.2 ABIOMED, Inc.: Recent Developments 75
12.3 Calon Cardio-Technology Ltd. 76
12.3.1 Overview 76
12.3.2 Calon Cardio-Technology Ltd.: Recent Developments 77
12.4 Maquet GmbH (Getinge AB) 77
12.4.1 Overview 77
12.4.2 Maquet GmbH (Getinge AB): Recent Developments 78
12.5 LivaNova PLC 79
12.5.1 Overview 79
12.5.2 LivaNova PLC: Recent Developments 79
12.6 Evaheart Medical USA, Inc. (Asahi Kasei Corp.) 80
12.6.1 Overview 80
12.6.2 Evaheart Medical USA, Inc.: Recent Developments 80
12.7 Fresenius Medical Care AG & Co. KGaA (XENIOS AG) 81
12.7.1 Overview 81
12.7.2 Fresenius Medical Care AG & Co. KGaA (XENIOS AG): Recent Developments 81
13 Annexure 83
13.1 Abbreviations 83

List of Table:

TABLE 1 REGULATORY STATUS OF GLOBAL VENTRICULAR ASSIST DEVICES MARKET 19
TABLE 2 GLOBAL VENTRICULAR ASSIST DEVICES MARKET REVENUE BY REGIONS, 2018–2025 ($MILLION) 45
TABLE 3 OTHER PROMINENT VENDORS OF VENTRICULAR ASSIST DEVICES MARKET 53
TABLE 4 MEDTRONIC PLC: OFFERINGS 54
TABLE 5 MEDTRONIC PLC: RECENT DEVELOPMENTS 54
TABLE 6 ABBOTT LABORATORIES: PRODUCT OFFERINGS 62
TABLE 7 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 62
TABLE 8 RELIANTHEART INC.: OFFERINGS 68
TABLE 9 RELIANTHEART INC.: RECENT DEVELOPMENTS 68
TABLE 10 JARVIK HEART, INC.: PRODUCT OFFERINGS 70
TABLE 11 JARVIK HEART, INC.: RECENT DEVELOPMENTS 70
TABLE 12 BERLIN HEART GMBH: PRODUCT OFFERINGS 72
TABLE 13 BERLIN HEART GMBH: RECENT DEVELOPMENTS 73
TABLE 14 BIVACOR: SNAPSHOT 75
TABLE 15 ABIOMED, INC.: SNAPSHOT 76
TABLE 16 CALON CARDIO-TECHNOLOGY LTD.: SNAPSHOT 78
TABLE 17 MAQUET GMBH (GETINGE AB): SNAPSHOT 79
TABLE 18 LIVANOVA PLC.: SNAPSHOT 80
TABLE 19 EVAHEART MEDICAL USA, INC.: SNAPSHOT 81
TABLE 20 XENIOS AG (FRESENIUS MEDICAL CARE AG & CO. KGAA): SNAPSHOT 82

 List of Charts
CHART 1 GLOBAL MEDICAL DEVICES MARKET SEGMENTATION 9
CHART 2 RESEARCH METHODOLOGY OF GLOBAL VENTRICULAR ASSIST DEVICES MARKET 14
CHART 3 GLOBAL VENTRICULAR ASSIST DEVICES MARKET REVENUE, 2018–2025 ($MILLION) 17
CHART 4 SEGMENTATION OF GLOBAL VENTRICULAR ASSIST DEVICES MARKET 22
CHART 5 PEST ANALYSIS OF GLOBAL VENTRICULAR ASSIST DEVICES MARKET 22
CHART 6 PORTER 5 FORCES ON GLOBAL VENTRICULAR ASSIST DEVICES MARKET 24
CHART 7 MARKET DYNAMICS – DRO ANALYSIS 25
CHART 8 DRO – IMPACT ANALYSIS OF GLOBAL VENTRICULAR ASSIST DEVICES MARKET 29
CHART 9 KEY STAKEHOLDERS OF THE GLOBAL VENTRICULAR ASSIST DEVICES MARKET 30
CHART 10 GLOBAL VENTRICULAR ASSIST DEVICES MARKET BY PRODUCT SEGMENTATION, 2018 (%) 31
CHART 11 GLOBAL VENTRICULAR ASSIST DEVICES MARKET BY TECHNOLOGY SEGMENTATION, 2025 (%) 32
CHART 12 GLOBAL LEFT VENTRICULAR ASSIST DEVICES MARKET FORECAST, 2018–2025 ($MILLION) 33
CHART 13 GLOBAL RIGHT VENTRICULAR ASSIST DEVICES MARKET FORECAST, 2018–2025 ($MILLION) 34
CHART 14 GLOBAL BIVENTRICULAR ASSIST DEVICES MARKET FORECAST, 2018–2025 ($MILLION) 35
CHART 15 GLOBAL VENTRICULAR ASSIST DEVICES MARKET BY DESIGN SEGMENTATION, 2018 (%) 36
CHART 16 GLOBAL VENTRICULAR ASSIST DEVICES MARKET BY APPLICATION SEGMENTATION, 2018 (%) 38
CHART 17 GLOBAL VENTRICULAR ASSIST DEVICES MARKET BY APPLICATION SEGMENTATION, 2025 (%) 39
CHART 18 GLOBAL BRIDGE-TO-TRANSPLANT (BTT) THERAPY MARKET FORECAST, 2018–2025 ($MILLION) 39
CHART 19 GLOBAL DESTINATION THERAPY MARKET FORECAST, 2018–2025 ($MILLION) 40
CHART 20 GLOBAL BRIDGE-TO-RECOVERY (BTR) THERAPY MARKET FORECAST, 2018–2025 ($MILLION) 41
CHART 21 GLOBAL BRIDGE-TO-CANDIDACY (BTC) THERAPY MARKET FORECAST, 2018–2025 ($MILLION) 42
CHART 22 GLOBAL VENTRICULAR ASSIST DEVICES MARKET BY GEOGRAPHICAL SEGMENTATION, 2018 (%) 44
CHART 23 GLOBAL VENTRICULAR ASSIST DEVICES MARKET BY GEOGRAPHICAL SEGMENTATION, 2025 (%) 45
CHART 24 VENTRICULAR ASSIST DEVICES MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION) 46
CHART 25 VENTRICULAR ASSIST DEVICES MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION) 48
CHART 26 VENTRICULAR ASSIST DEVICES MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION) 49
CHART 27 VENTRICULAR ASSIST DEVICES MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION) 51
CHART 28 MEDTRONIC PLC: OVERVIEW SNAPSHOT 57
CHART 29 MEDTRONIC PLC: BUSINESS UNITS 59
CHART 30 MEDTRONIC PLC: GEOGRAPHIC PRESENCE 60
CHART 31 MEDTRONIC PLC: SWOT ANALYSIS 61
CHART 32 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT 64
CHART 33 ABBOTT LABORATORIES: BUSINESS UNITS 65
CHART 34 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE 66
CHART 35 ABBOTT LABORATORIES: SWOT ANALYSIS 67
CHART 36 RELIANTHEART INC.: SWOT ANALYSIS 69
CHART 37 JARVIK HEART, INC.: SWOT ANALYSIS 71
CHART 38 BERLIN HEART GMBH: SWOT ANALYSIS 73